Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.

ABSTRACT:

Background

Relapsed or refractory (R/R) disease following frontline treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) represents a significant clinical challenge in the management of diffuse large B-cell lymphoma (DLBCL).

Objectives

To address unmet medical needs, comprehensive clinical data on R/R DLBCL in real-world settings are warranted.

Design

A retrospective observational study including patients from a tertiary medical center and a national population-based cohort.

Methods

We conducted a retrospective cohort study of R/R DLBCL, derived from 665 consecutive patients treated with R-CHOP. Furthermore, a population-based cohort from Taiwan's National Health Insurance Research Database was established for external v

SUBMITTER: Cheng CL 

PROVIDER: S-EPMC12681623 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature